Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inflexal V 2010/2011 Influenza Vaccine Immunogenicity and Safety
NCT01306305Phase 4Completed
- Sponsor
- Crucell
- Start
- Jun 2010
- Primary completion
- Jul 2010
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Inflexal V in influenza (2 arms), sponsored by Crucell. Primary endpoints: Seroconversion Rate at Day 22, Seroprotection Rate at Day 22 and 1 more. Started Jun 2010; status: completed.
02
Drugs
Inflexal V
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01306305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01306305.